Anavex gains compositions patent for Alzheimer's drug candidate

• Anavex Life Sciences (NASDAQ:AVXL) was awarded a compositions patent for ANAVEX2-73 (blarcamesine), its candidate for Alzheimer's and central nervous system disorders.
• The patent covers certain crystal forms of the candidate's compositions and processes of preparation. It is valid until at least October 2036.
• ANAVEX2-73 (blarcamesine) is in phase 3 for Alzheimer's and Rett Syndrome, and earlier stages for other conditions including Parkinson's and Parkinson's dementia.

More on Anavex

• Anavex And The Antioxidant Treatment Of Alzheimer's Disease

• Buy Anavex For Its Likely Positive Alzheimer's Disease Data